DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x73cdd/medipoint) has announced the addition of the "MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Global Analysis and Market Forecasts" report to their offering.
High-sensitivity troponin tests will increasingly replace previous generation assays over the next five years, and cardiac biomarker diagnostics could go beyond the typical laboratory and hospital settings to individuals with no-known history of heart disease in the future, says the latest report from research and consulting firm The authors.
According to the company's new research*, some cardiology experts think manufacturers should invest in developing tests aimed at the normal, healthy population, with the goal of monitoring cardiac health and treating potential problems before they represent a serious threat.
Dr. Savade Solanki, The authors's Senior Analyst Covering In Vitro Diagnostics, says: The sensitivity of these troponin assays are expected to reach a level where monitoring in the healthy population outside the hospital setting is a could be feasible.
Analogous to cholesterol monitoring, one hypothesis is that troponin levels could be tracked over weeks and months, and this could potentially allow detection of low levels of myocardial injury and identification of the source.
Cardiac troponins are currently considered the gold-standard in biomarkers for the diagnosis of Acute Coronary Syndromes (ACS) and Myocardial Infarction (MI). Typically, suspected ACS patients receive a troponin biomarker test as a matter of course.
ACS in vitro diagnostic testing has been a mainly laboratory-only process, with only a minority of hospitals presently carrying out tests at the Point-Of-Care (POC), but some interviewed experts think that it may not be long before this testing method becomes much more common thanks to anticipated improvements in POC troponin sensitivity.
However, manufacturers targeting the laboratory-based cardiac biomarker diagnostics market may face resistance from cost-conscious healthcare facilities.
Despite the launch of improved sensitivity troponin assays, developers will find it difficult to stimulate new business in hospitals with competitor instruments, as laboratories are reluctant to replace existing instruments and brands with new ones, and are willing to wait for a high-sensitivity test to be available on their current platform, says Dr. Solanki.
The authors forecasts the US to remain the dominant share holder in the ACS in collective in vitro diagnostic testing reagents market across the US, China, Japan, India, Brazil, the UK, Spain, France, Germany and Italy until 2018. This share is expected to slip from 81% in 2012 to 78% in 2018, due to the increasing shares of Europe and emerging markets.
This report provides detailed analysis of the ACS diagnostic cardiac biomarkers market.
Key Topics Covered:
List of Tables
List of Figures
Current and Future Players
Market Drivers and Opportunities and Barriers
Country Outlooks and Forecasts
List of Tables
List of Figures
Mitsubishi Chemical Medience Corporation
For more information visit http://www.researchandmarkets.com/research/x73cdd/medipoint
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.